Fibroblast Growth Factor Receptor 1&2 Assay Targets Cell Growth & Tumor Progression State College, PA (31 August 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust preclinical testing portfolio to include a new Fibroblast Growth Factor Receptor 1&2 (FGFR1/2) assay primarily implicated in diabetes, kidney disease, and theRead More
INDIGO Biosciences Announces Addition of TPOR Assay to Pre-Clinical Portfolio
Thrombopoietin Receptor Indicated in Anemia & Blood Cancer Treatment Development State College, PA (10 August 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded its pre-clinical portfolio to include the Thrombopoietin Receptor (TPOR). Responsible for platelet production, TPOR is primarily used in developing treatments related to familial aplastic anemia andRead More
INDIGO Biosciences Expands Portfolio to Include Cannabinoid Type 1 Receptor
CB1R Assay Implicated in Cancer Therapies and Neurological Disorders State College, PA (13 July 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include a new Cannabinoid Type 1 Receptor (CB1R) assay, primarily used in developing cancer side effect-related treatments and implicated in the developmentRead More
INDIGO Biosciences Expands Preclinical Portfolio for Anemia and Oncology Research
Erythropoietin Receptor Assay Targets Red Blood Cell Development and Production State College, PA (20 April 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust preclinical testing portfolio to include a new Erythropoietin Receptor (EPOR) assay primarily used in the treatment of anemia and implicated in the development ofRead More
INDIGO Biosciences Expands Autoimmune-Focused Preclinical Testing Portfolio
Nuclear Factor of Activated T cells Assay Targets Preclinical Autoimmune and Oncology Research State College, PA (16 March 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include a new Nuclear Factor of Activate T cells (NFAT) assay used primarily for preclinical autoimmune research. ThisRead More
INDIGO Biosciences Expands Oncology-Focused Preclinical Testing Portfolio
Expansion Includes New Growth Factor Receptor and Transcription Factor Assays Targeting Preclinical Oncology Research State College, PA (5 January 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include five new assays used primarily for preclinical oncology research. These cell-based in vitro assays include fourRead More
INDIGO’s Preclinical Animal Model Platform Expands Zebrafish Offering
Expansion Meets Industry Demand for Cell-Based Preclinical Models for Cancer, Chemical, and Environmental Research State College, PA (6 October 2020) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems. Previously available only as a live-model system, INDIGO’sRead More
INDIGO Biosciences Announces Record Revenue for 2019
Company Shows Another Year of Record Growth and Advancements State College, PA (29 January 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, has announced a record earnings year for 2019. With final numbers to be released to Company Shareholders in the upcoming weeks,Read More
INDIGO Expands Discovery Platform to Include Zebrafish Assays
Expansion Meets Industry Demand for Pre-Clinical Models for Cancer and Environmental Research State College, PA (23 January 2020) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has announced the addition of four zebrafish assays to its portfolio. These additions both expand INDIGO’s robust portfolio of in vitro animal model assay systems andRead More
INDIGO Biosciences Welcomes New Member to Board of Directors
Mark McLoughlin Brings Four Decades of Healthcare Industry Experience to the Company’s Board State College, PA (13 August 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the appointment of Mark McLoughlin to the Company’s Board of Directors. Mark brings four decades of healthcare industry experience to theRead More